CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma.
To the editor. Mosunetuzumab (mosu), a CD20×CD3 bispecific antibody, has emerged as an effective therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL), yielding durable remissions even in heavily pretreated patients. In the pivotal phase II GO29781 study, mosu achieved substantial clinical activity and subsequently received accelerated approval in this setting. Updated analyses confirmed its long-term benefit, with complete remission (CR) rates approaching 60% and a 2-year p...